Sitemap - 2025 - On The Pen
There’s a Guy in Washington Fighting for Your GLP-1, and You’ve Probably Never Heard of Him
Move Over Retatrutide, Protagonist Just Became Your Antagonist
Losing Zepbound Coverage? This Tool Might Give you and 80% Shot at Keeping It
If You Have Ever Loved Someone with Alzheimer’s, Hope May Be Near. Read This
They Scanned Zepbound Users Brains… and Found Food Noise?
“Vikingtide” (VK2735)Enters Phase 3 and the Underdog Is Not Holding Back
You Won’t Believe What Semaglutide Just Did in Type 1 Diabetes
Maritide Results Leave Investors Feeling Pukey
Lilly’s Rare ADA Investor Call: What Actually Mattered
Lilly’s Worst Nightmare: Compounders Directly Challenged Lilly’s Tirzepatide Patent In Court
Cardiology Just Declared War on Obesity. Pemvidutide May Be One of Its Strongest Weapons
Orforglipron’s ADA 85 Data Cements Its Place as the First Non-Peptide Oral GLP-1 Contender
Wegovy 7.2 mg Helped 33% Lose 25% or More
Water vs. Diet Soda: The Switch That Doubled Weight Loss and Diabetes Remission
Obesity Finally Gets Its Own Standards of Care: ADA 2025 Opens with a Game Changing Shift
BREAKING: Novo Goofs, Canada Expires the Ozempic Patent
The FDA Wins. The OFA Loses. And Semaglutide Is Off the Shortage List for Good
⚠️ It’s Not Just Powder and Water. The Hidden Danger of Research Grade Cagrilintide
Lilly Finally Fulfills Our Call: All Zepbound Vials Are Coming
Lilly’s Quiet Contender? Eloralintide Posts Impressive Weight Loss Just as Novo Takes the Spotlight
🚨 BREAKING: Senators Move to BAN Drug Ads, A Long Touted RFK Jr. Policy
🚨 BREAKING: Novo Moves Amycretin Into Phase 3. This Might Be the Drug They Were Really Waiting For
The Ozempic Thyroid Cancer Scare Just Got Debunked
Grateful for One More Day: My 40th Birthday Reflection
Ozempic, Wegovy, and Rybelsus Will Now Warn of Rare Vision Loss Risk in Europe
BREAKING: The Bill That Could Force Medicare to Cover Obesity Drugs Is Here
You Might Never Have to Take a Weekly GLP-1 Shot Again. Here’s What Lilly Just Did
More U.S. Teens Are Starting Wegovy. Are We Ready for This Conversation?
Three Myths Holding Back the GLP-1 Community
Does Using 800% More Ozempic Per Week Equal Better Outcomes?
Novo Just Admitted This About Compounded Semaglutide
We Need a Shared Language Around GLP-1s.
I Almost Collapsed at the Store. Was It Mounjaro?
My Heart is Trying to Warn Me.
Microdosing GLP-1 is Not an Obesity Treatment
Novo Nordisk Just Sued Another Compounder. This Time, Amble
First Month $199 Wegovy Offer: Novo Should Cement This Price
Cigna To Cap Zepbound and Wegovy Copays at $200. Rare Win for Patients or PBM Survival Mode?
Canada’s Cheap Drugs Are Coming? The FDA Says They’ll Help States Make It Happen
They Came for the Group. Now They’re Coming for Me.
🚨 BREAKING: Trump Admin To Officially Set Price Targets for Zepbound and Wegovy
GLP-1s and Alcohol? Altimmune Just Launched a Phase 2 Trial to Find Out
Will GLP-1 Compounds Become the Next Cash Only Medical Market?
FOLLOW-UP: Here’s The EMR Sending Threatening Letters to Compound GLP-1 Prescribers
EXCLUSIVE: Doctor Threatened With Financial Blackout Over Compounded GLP-1
Facebook Just Nuked Us. But They Can't Stop Us.
Novo Nordisk: An Honest Assessment
Novo Nordisk CEO Abruptly Steps Down Amid Market Shifts, Lilly Pressure, and Oral GLP-1 Scramble
What Eli Lilly Thinks of Trumps Plan + Calley Means Promises Cheaper GLP-1's
We did it. #1 Rising Substack in Health & Wellness.
Democrats Move to Codify Trump’s Drug Pricing Order
Listen to OTP Live Right Now On Cinci's WVXU!
Compounded Tirzepatide: We Now Have the Judge’s Opinion, in Massive Blow to 503B’s
Inside Trump’s Drug Price Order: What It Says and How It Could Work
Trump Most Favored Nation Presser Summary
CVS Dropped Zepbound. Today, the SURMOUNT-5 Data Dropped Back.
BREAKING: President Trump Announces Executive Order to Cut Prescription Drug Costs
To The Mothers, and Those Mothering
The Real Reason They Hate Ozempic
They Said It Wouldn’t Work. Now We’re #4. Let’s Get to #1!
Compound Tirzepatide: Hundreds of Thousands Losing Access. This Proposal Could Change That
Zepbound Lawsuit: Lilly Wins, Don't Let Patients Lose
The Hims + Novo Deal Reveals a Quiet Concession About Compound Semaglutide
I Need Your Help Today: Operation Top 10 by 40!
Rite Aid is Quietly Cutting Off GLP-1 Patients. Why Other Pharmacies May Follow
CVS Is Dropping Zepbound. Here Is What You Can Do Right Now
I’m shifting gears to push even harder… And it Feels Good!
The WHO Just Backed GLP-1s for Obesity. What Took So Long?
Oral Wegovy Is Headed to the FDA. But It’s Not the 50 mg.
Inside the Tirzepatide Supply Number That Could Bring The FDA Lawsuit Crashing Down
Zepbound Surges, Orforglipron Impresses, and Lilly Keeps the Crown. For Now.
Over 500 Strong, and Just Getting Started
SHOCKING DATA: Will Zepbound Finally Be Covered By Employers?
The Study That Might Finally Break Open Access to GLP-1s
Big Tech in Obesity Care: The Storefront vs the Supercenter
Compound GLP-1 PubMed Study: What It Doesn’t Tell Us
Compound GLP-1 PubMed Data: What It Didn’t Tell Us
Compounded GLP-1 Under Fire Again: What Today’s Study Didn’t Tell Us
Compounded GLP-1s Are Under Fire Again: What Today’s Study Doesn’t Tell Us
Fighting for Obesity Care: Inside My Advocacy Trip to Washington, DC
Why Obesity Medicine Needs a New Voice, Yours
Lilly Sues Four More Over Compounded Tirzepatide and the Fallout Has Just Begun
High Dose Semaglutide Incoming! How Much Will it Cost? // OTP TWD 4.22.25
BREAKING: Novo Nordisk Has Filed for Approval for High Dose Oral Semaglutide
Getting Insurance To Cover Skin Removal Surgery // OTP Eps 109
Orforglipron: Phase 3 Data Shows Ozempic-Like Results, In Pill Form
BREAKING : Lilly Extends Zepbound Savings Cards Through End of 2025
Counterfeit Ozempic at Pharmacies! // OTP TWD 4.15.25
The Counterfeit Crisis Just Got Worse: More Ozempic Fakes Found Inside Our Supply Chain
GLP-1 Slow Responders: Dr Matthea Rentea // OTP Eps 108
Grow-Zempic!? These Students Discoverd a GLP-1 Plant!
Noom CEO Geoff Cook Interview: Wall Street Journal GLP-1 Cost Ad
GLP-1 Medicare Coverage: What is Going On // OTP TWD 04.08.2025
Zepbound for Life? New Data Shows Promise for Post GLP-1 Weight Maintenance Proceedure
Are GLP-1 Meds For Life? Fractyl’s CEO Says “Not So Fast!”
Fake Sugar: 👍 or 👎 for Weight Loss With Dr. Spencer Nadolsky // OTP Eps 107
Tirzepatide Compounds: Lilly Sues Pharmacies // OTP TWD 04.01.25
Lilly Suing Strive and Empower Pharmacies over Compound Tirzepatide
Zepbound Weight Loss Stalls: Tips and Tricks // OTP Eps 106
Transcript: On The Pen Interview with OFA Chairman, Lee Rosebush
Rare Exclusive Interview: OFA Chairman Sits Down with OTP to Talk Tirzepatide Lawsuit
Where Does Compound Tirzepatide Stand 3/19/25
Everything You Need to Know About GLP-1, But Your Doctor Won’t Tell You
Compound Tirzepatide: I’m Just Weary of it All
Ozempic: Setting the Microdosing Strategy Straight w/ Dr Tyna Moore // OTP EPS 105
Compound Tirzepatide Latest // Cagrisema Disappoints Again // Great Vikingtide News
UPDATE [March 7, 2025]: OFA takes tirzepatide case to appeals court as legal battle evolves
Obesity Bias in Medicine With Dr. Toomer // OTP Eps 104
The Next GLP-1 Is A Pill: What to Expect for Weight Loss
Novo Cuts Wegovy Price in Half, Offers $499/mo Meds to the Uninsured and Underinsured
Compound GLP-1 Accessibility + World Obesity Day // OTP TWD 03.04.25
Compound Tirzepatide Latest Updates // @Mike.OnAMssion2 Joins // OTP Eps 103
OFA Fires Back at FDA in Tirzepatide Case, Redactions Raise Questions as Decision Looms
Lilly Drops Zepbound Price, Compounders Sue FDA (again) OTP TWD 2.25.25
Compound Tirzepatide Lawsuit Update / GLP-1 Heart Health w Dr Simin Lee / OTP Eps 102
503A Compound Tirzepatide Deadline Is Here, What Next? // OTP TWD 2.18.25
Zepbound Weight Loss and Cancer Diagnosis // OTP Eps 101
Lilly Announces Next Gen Tirzepatide
GLP-1 Talk Show: An Emotional 100th On The Pen Live
Zepbound and Retatrutide News: Lilly Q4 Earnings Call Recap
Novo Nordisk Q4 '24 Earnings Call: Obesity Medicine Implications
Like Retatrutide But In A Pill? OTP TWD 2.4.25
463 Pound Zepbound Weight Loss // OTP Eps 99
503b Compounder Rocked by FDA Audit + OFA v FDA Trial Update
Kelly Matthew of GLP1 Real Talk Joins! OTP Eps 97
Massive Zepbound and Wegovy News // OTP TWD 1.21.25
Compounders Win Small Battle in War Over Zepbound and Mounjaro Shortages
Legal Expert: Compound Tirzepatide Trial Update || OTP Eps 96